Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Next Previous
Trial Profile

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Cynapsus Therapeutics

Most Recent Events

  • 19 Jul 2016 Results published in the Movement Disorders (2016).
  • 21 Apr 2016 Results assessing safety of apomorphine presented at the 68th Annual Meeting of the American Academy of Neurology.
  • 21 Apr 2016 Results (subgroup analysis) assessing effects of apomorphine on the rapid reversal of OFF episodes in PD presented at the 68th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top